Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Holdings -- Ignore unavailable to you. Want to Upgrade?

To: Link Lady who wrote (131)	11/19/1998 12:56:00 PM
From: Link Lady	Read Replies (1) \| Respond to of 224

This was in my e-mail, thought I'd pass it along. Attention: Mrs. Wendy Cusack Biotech Holdings is not working directly on a new product for Juvenile Diabetes. However, there is reason to think that DIAB II, as an insulin-sensitizing drug, can reduce the amount of insulin that needs to be injected for insulin-injecting Type II diabetics (Biotech has some clinical data suggesting this as well), so there the possibility that Type I diabetics could also be helped to some extent. I am adding your name to our e-mail information list so that you will receive news about the Company and DIAB II on a regular basis. If you have questions please call me toll-free at 1 888 216 1111, 8 a.m to 5 p.m. (Pacific time).